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drugs for severe diseases to become available earlier in their development cycle but 
risks approving ineffective and/or unsafe drugs.
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Objectives: To study patient’s out-of-pocket expenditures in patients taking oral 
oncology medication for the treatment of Multiple Myeloma who are enrolled in 
a specialty pharmacy program. MethOds: A retrospective analysis of pharmacy 
claims and reimbursement data for oncology patients enrolled in a specialty phar-
macy program and receiving biologic drugs from January 1, 2013 through October 
31, 2013 was conducted. Patients with a primary diagnosis of Multiple Myeloma 
(ICD-9 CM: 203.xx) prescription data were included. There were no exclusion criteria. 
The distribution of out-of-pocket patient’s costs per prescription were performed 
comparing average co-pay responsibility per prescription after insurance to aver-
age patient co-pay per prescription after funding assistance. Results: A total 
of 22,566 prescriptions were included. The average patient co-pay responsibility 
after insurance was $435.00 per prescription and the average patient co-pay after 
funding assistance was $81.00 per prescription. This resulted in 12,822 (91.17%) of 
the prescriptions had a patient co-pay of under $10.00 after funding assistance. 
The patient’s insurance type was as follows: private insurance was 59%, Medicare 
was 25%, Pharmacy Benefit Manager was 10%, Tricare was 1%, and Medicaid was 
5%. cOnclusiOns: In this retrospective analysis of pharmacy and financial claims 
data, Multiple Myeloma patients significantly reduced their out-of-pocket expen-
ditures, from an average of $435.00 to $81.00 by the specialty pharmacy gaining 
funding assistance for the patient.
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Objectives: To assess imaging and treatment patterns in head and neck cancer 
(HNC) patients using a large commercial-insurance database from the United States 
(U.S.). MethOds: We used the Marketscan® Research Databases (2007-2011) to 
identify adults with HNC (oral, pharynx, paranasal sinus, larynx) using ICD-9 codes. 
We evaluated three periods of imaging and treatment patterns: 1) three months 
pre-diagnosis, 2) diagnosis-to-treatment initiation, and 3) post-treatment initia-
tion. Patients receiving single-imaging modalities and multiple-imaging modali-
ties were evaluated in relation to surgery, chemotherapy, radiation therapy, and 
combinations. Imaging and treatment intensity and variability by cancer types and 
geographic regions (Northeast, North Central, South, and West) were assessed using 
multinomial and multivariate logistic regression. Results: 80,987 patients were 
analyzed (39% female, mean age: 60 years). During pre-treatment, comparing all 
cancer types to oral cancer, pharynx cancer patients had the greatest likelihood 
of single-modality imaging and multiple-modality imaging. Patients with higher 
comorbidity index scores were more likely to receive more intensive imaging prior 
to treatment. Pre-treatment imaging was more likely to occur in other regions com-
pared to West (OR range: 1.07-1.29), with consistent imaging patterns versus the 
West following treatment. There was limited regional variability in single and/or 
multiple intervention patterns. In the post-treatment period, patients receiving 
multiple treatment interventions, a proxy for advanced cancer, were more likely to 
undergo PET/CT. A high portion of larynx cancer patients received surgery (37%). 
Pharynx cancer patients were more likely to receive radiation therapy (24%) and/or 
chemotherapy (30%). During all phases combined, females were less likely to get 
imaging of any type (x-ray, CT, or PET/CT) (OR range: 0.71-0.91). cOnclusiOns: 
Commercially-insured HNC patients in the U.S. vary in imaging intensity and in the 
types of imaging modalities used, prior to and following initial diagnoses. Receiving 
multiple treatment interventions was associated with undergoing multiple imaging 
tests and more specifically, PET/CT.
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Objectives: To describes treatment patterns among patients initiating regorafenib, 
an oral kinase inhibitor indicated for the treatment of metastatic colorectal cancer 
in patients who have tried other first-line therapies. MethOds: Pharmacy and 
medical claims from Humana, a large national U.S. payer, were used. The study 
sample included patients age 19 to 89 years with at least one claim for regorafenib 
between 9-27-2012 and 6-1-2013. A subset of patients with pharmacy and medical 
benefits, as well as pre-index continuous enrollment of at least 12 months, was 
used to examine prior exposure to chemotherapy, radiation, and biologic thera-
pies. Patients were followed until death, disenrollment or study end date (10-31-
2013). Results: A total of 407 patients with claims for regorafenib were identified. 
The mean age was 66.4 years, 53.1% were male, and median length of follow up was 
140 days (range of 0-357 days). Median length of pre-index continuous enrollment 
was 779 days. The majority resided in the southern (51.6%) and midwestern (26.0%) 
U.S. and most patients had Medicare Advantage (26.0%) or Medicare Part D (69.3%) 
coverage. A total of 91 regorafenib patients met all inclusion/exclusion criteria. 
Metastatic cancer diagnosis was observed in 93.4% of patients; the majority had 
liver metastases. Common pre-index comorbidities included hypertension (72.5%), 
fluid/electrolyte disorders (41.8%), chronic pulmonary diseases (25.3%), diabetes 
(34.1%), and depression (15.4%). Evidence of chemotherapy, biologic therapy, and 
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Objectives: Drug shortages are a global problem. While extensively studied in the 
United States, numbers about drug shortages in European countries are scarce. This 
study aims to investigate publically available data about drug shortages in European 
countries in order to reveal a typology of drug shortages in Europe. MethOds: A 
standardized reporting template was designed based on a literature search to collect 
and structure information. Countries offering an online reporting system for drug 
shortages such as Belgium, The Netherlands, England, Italy, France, Germany and 
Spain are included in this study. The online reporting systems were consulted in 
May 2013. Typology and causes of drug shortages are mapped and a sub-analysis is 
performed for essential medicines and oncology drugs. Results: Majority of drugs 
reported to suffer from shortage (n= 671) are branded (61%), oral drugs (51%) that 
equally affect different disease domains. When considering essential medicines 
(n= 200) and oncology drugs (n= 71), generics (55% for essential drugs, 64% for oncol-
ogy drugs) and injectables (52% for essential drugs, 79% for oncology drugs) are more 
involved. Causes for drug shortages are underreported, as the cause is not known 
in 66% of the cases (n= 671). Production problems are reported in 27% of the cases 
(n= 671). Results are subjected to the different scopes of the considered reporting 
systems. cOnclusiOns: Reporting of drug shortages in Europe needs to be stand-
ardized and more transparency about the reasons for drug shortages is required to 
understand the problem. A link between production problems and market attrac-
tiveness and market capacity is recognized to be at the root of drug shortages in 
U.S. Such insights are highly lacking in Europe. Monitoring of the effect of national 
and European health policies on the sustainability of the drug market is required 
to present fundamental solutions for the problem of drug shortages in Europe.
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Objectives: Ponatinib was temporarily withdrawn by the FDA in October 2013 fol-
lowing safety concerns arising from its Phase III trial. This drug had previously been 
approved under the accelerated approval pathway. Three other oncologics have been 
withdrawn under similar conditions, further adding to concerns with this pathway. 
This research aims to provide an up-to-date systematic analysis of all oncolog-
ics approved under this pathway and analyse the time delay in obtaining regular 
approval. MethOds: Publically available assessments of any oncologic approved 
under the FDA accelerated approval pathway were sourced and the dates of acceler-
ated approval and conversion to regular approval were extracted. Results: 41 onco-
logics across 50 indications have been assessed under the FDA accelerated approval 
pathway, all but two of which have been approved. Of the approved indications, 50% 
(24/48) have been converted to regular approval with an average delay of 53 months 
(range 13-151 months). 6% (3/48) have been withdrawn from the market due to lack 
of efficacy and/or safety concerns arising from Phase III data. 44% (21/48) have not 
been converted to regular approval despite being on the market for an average of 
45 months (range 4–109 months). In these cases the mandatory confirmatory trials 
have not been completed and to date the FDA has not withdrawn a single oncologic 
from the market for not conducting the confirmatory trial. cOnclusiOns: 21 onco-
logic indications approved under the accelerated approval process have not been 
converted to regular approval despite some being on the market for up to 9 years. 
Given that 11% (3/27) of the drugs that have conducted confirmatory trials have been 
withdrawn, completion of confirmatory data should become a strict, non-negotiable 
requirement with a defined time limit by which the data must be submitted. A fail-
ure to do so should see the FDA automatically withdrawing their license.
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Objectives: The European Medicines Agency (EMA) approved 19 oncologics across 
25 indications on the basis of pivotal Phase II data lacking an active comparator 
(Macaulay, ISPOR Dublin 2013). Approval was typically granted for indications in 
which there was no therapeutic alternative where a response rate of ≥ 35% was 
demonstrated. This research aims to define the circumstances under which the 
Food and Drug Administration (FDA) will approve oncologics on the basis of pivotal 
Phase II data and compare to those of the EMA. MethOds: A systematic search 
was undertaken for FDA oncologic submissions based on pivotal Phase II data and 
the acceptance decision, indication, and level of benefit were extracted. Results: 
31 oncologics across 38 indications were submitted to the FDA on the basis of piv-
otal Phase II data. All of which were non-comparative and 36 were approved. This 
included all drugs approved by the EMA on this basis except trabectidin. 32 indi-
cations were approved under the accelerated approval pathway, only 47% (15/32) 
of which have been converted to regular approvals. Two of these drugs have been 
subsequently withdrawn from the market as they failed to show benefit in confirma-
tory trials (gefitinib and gemtuzumab), neither of which were EMA-approved for 
these indications. 72% (23/32) were FDA designated orphan indications. 78% (25/32) 
indications were for lines of therapy or diseases that had no relevant therapeutic 
alternatives. The response rates of approved drugs ranged from 11%-86%, while 
13 indications were approved with response rates of < 35%, which included the 
2 withdrawn drugs. cOnclusiOns: Pivotal Phase II data can support FDA onco-
logic approvals for indications that lack therapeutic alternatives and demonstrate 
response rates of ≥ 10% (versus ≥ 35% for the EMA). The lower threshold enables more 
